The Themis2 Polyclonal Antibody (CAB15355) is a powerful tool for researchers studying Themis2, a crucial protein involved in immune regulation. This antibody, generated in rabbits, exhibits high reactivity with human samples and has been validated for use in Western blotting applications. By binding to the Themis2 protein, this antibody enables precise detection and analysis in a variety of cell types, making it ideal for investigations in the fields of immunology and cancer research.Themis2 plays a key role in immune system function by regulating immune responses and maintaining immune balance.
Understanding the function of Themis2 is essential for exploring its potential implications in diseases such as cancer, autoimmune disorders, and chronic inflammation. Researchers can use this antibody to unravel the mysteries surrounding Themis2 and pave the way for the development of targeted therapies aimed at modulating immune responses in various disease contexts.Overall, the Themis2 Polyclonal Antibody (CAB15355) is a valuable tool for researchers seeking to deepen their understanding of immune regulation and its impact on human health.
Product Name:
THEMIS2 Rabbit Polyclonal Antibody
SKU:
CAB15355
Size:
20uL, 100uL
Isotype:
IgG
Host Species:
Rabbit
Reactivity:
Human,Mouse,Rat
Immunogen:
Recombinant fusion protein containing a sequence corresponding to amino acids 1-260 of human THEMIS2 (NP_004839.2).
Predicted to be involved in T cell receptor signaling pathway and regulation of B cell activation. Predicted to be active in cytoplasm and nucleus.
Purification Method:
Affinity purification
Gene ID:
9473
Storage Buffer:
Store at -20℃. Avoid freeze / thaw cycles.Buffer: PBS with 0.01% thimerosal,50% glycerol,pH7.3.
Western blot analysis of various lysates using THEMIS2 Rabbit pAb (CAB15355) at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution.Lysates/proteins: 25μg per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit (AbGn00020).Exposure time: 30s.
